California Public Employees Retirement System Has $6.36 Million Stock Position in Reata Pharmaceuticals, Inc. (NASDAQ:RETA)

California Public Employees Retirement System lifted its position in Reata Pharmaceuticals, Inc. (NASDAQ:RETA) by 1.9% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 51,431 shares of the company’s stock after acquiring an additional 947 shares during the period. California Public Employees Retirement System owned about 0.15% of Reata Pharmaceuticals worth $6,358,000 as of its most recent SEC filing.

Several other hedge funds have also recently added to or reduced their stakes in the company. ProShare Advisors LLC boosted its stake in Reata Pharmaceuticals by 2.3% in the 3rd quarter. ProShare Advisors LLC now owns 4,602 shares of the company’s stock worth $448,000 after purchasing an additional 102 shares during the period. Treasurer of the State of North Carolina boosted its position in shares of Reata Pharmaceuticals by 1.4% in the third quarter. Treasurer of the State of North Carolina now owns 8,820 shares of the company’s stock worth $859,000 after buying an additional 120 shares during the period. Perigon Wealth Management LLC acquired a new stake in shares of Reata Pharmaceuticals in the fourth quarter worth $26,000. Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in shares of Reata Pharmaceuticals by 9.4% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,823 shares of the company’s stock valued at $349,000 after buying an additional 243 shares in the last quarter. Finally, Paloma Partners Management Co raised its position in Reata Pharmaceuticals by 1.8% during the third quarter. Paloma Partners Management Co now owns 25,248 shares of the company’s stock valued at $2,460,000 after buying an additional 436 shares during the period. Institutional investors and hedge funds own 64.30% of the company’s stock.

RETA has been the topic of a number of research reports. Smith Barney Citigroup dropped their target price on Reata Pharmaceuticals from $260.00 to $234.00 in a report on Wednesday, November 25th. Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell reduced their price objective on Reata Pharmaceuticals from $260.00 to $234.00 in a research report on Wednesday, November 25th. Finally, Cantor Fitzgerald boosted their target price on Reata Pharmaceuticals from $169.00 to $220.00 in a research note on Tuesday, November 10th. Six analysts have rated the stock with a buy rating, The company has a consensus rating of “Buy” and a consensus target price of $251.25.

Shares of NASDAQ RETA opened at $116.79 on Tuesday. The business’s 50-day simple moving average is $116.93 and its 200-day simple moving average is $120.51. Reata Pharmaceuticals, Inc. has a 52 week low of $88.17 and a 52 week high of $209.91. The firm has a market cap of $3.98 billion, a price-to-earnings ratio of -10.29 and a beta of 1.57.

Reata Pharmaceuticals Profile

Reata Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, develops novel therapeutics for patients with serious or life-threatening diseases by targeting molecular pathways that regulate cellular metabolism and inflammation. The company is developing Phase III clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney disease(CKD) caused by Alport syndrome, as well as for a form of pulmonary arterial hypertension associated with connective tissue disease; omaveloxolone that is Phase II clinical trial to treat Friedreich’s ataxia; and conduct phase 2 study for various form of CKD, such as IgA nephropathy, type 1 diabetic, and focal segmental glomerulosclerosis.

See Also: What is a Fibonacci Channel?

Receive News & Ratings for Reata Pharmaceuticals Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Reata Pharmaceuticals and related companies with MarketBeat.com’s FREE daily email newsletter.

Powered by WPeMatico